# AMGEN INC: Biologic license for PAVBLU

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | AMGEN INC |
| Product | PAVBLU |
| Generic / ingredient | AFLIBERCEPT-AYYH |
| Approval | Biologic license (BLA) |
| Application | BLA761298 |
| Decided | 2026-10-22 |
| Panel / class | INJECTABLE, INJECTION |

## Why this score
- Decided in the last 30 days.
- A new product launch.

Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration) (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761298). Last refreshed: 2026-11-03T05:14:00.980Z.
From openFDA (PMA and Drugs@FDA). openFDA can lag FDA decisions by days to weeks. Drug supplement types follow the FDA submission class (labeling and REMS, manufacturing/CMC, efficacy, other). Company and product level only. Verify on FDA databases before relying on an approval.